Yunbing Wang
by seuh8j4 | Oct 17, 2024
LnRiLWZpZWxke21hcmdpbi1ib3R0b206MC43NmVtfS50Yi1maWVsZC0tbGVmdHt0ZXh0LWFsaWduOmxlZnR9LnRiLWZpZWxkLS1jZW50ZXJ7dGV4dC1hbGlnbjpjZW50ZXJ9LnRiLWZpZWxkLS1yaWdodHt0ZXh0LWFsaWduOnJpZ2h0fS50Yi1maWVsZF9fc2t5cGVfcHJldmlld3twYWRkaW5nOjEwcHggMjBweDtib3JkZXItcmFkaXVzOjNweDtjb2xvcjojZmZmO2JhY2tncm91bmQ6IzAwYWZlZTtkaXNwbGF5OmlubGluZS1ibG9ja311bC5nbGlkZV9fc2xpZGVze21hcmdpbjowfQ==
TW9udHNlcnJhdDo2MDAscmVndWxhciw1MDA=
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
Yunbing Wang
Sichuan University, China
2024
TW9udHNlcnJhdDo2MDAscmVndWxhciw1MDA=
Yunbing Wang is the Director of National Engineering Research Center for Biomaterials in China and Dean of College of Biomedical Engineering in Sichuan University. He received his Ph.D. from Fudan University in Shanghai, and completed postdoctoral studies at University of Minnesota. He had worked at Medtronic, Boston Scientific, Abbott and Cooper Vision for about 12 years before he moved back to university for academic work.
His research is focused on the development of biomaterials and implantable devices for various cardiovascular diseases treatment. He is well known for his exceptional contributions to a series of minimally invasive cardiovascular medical devices development and clinical applications. He has more than 300 scientific papers published, more than 500 patents granted, and more than 100 invited presentations made. He is the major inventor of the first commercialized bioresorbable patent foramen ovale (PFO) occluder for cardioembolic stroke treatment in the world (2023), the first commercialized bioresorbable cardiac occluder for congenital heart disease treatment worldwide (2022), the first commercialized bioresorbable drug eluting polymeric stent for coronary heart disease treatment (2011), and transcatheter self-expanding pulmonary valve for heart valve disease treatment with CE mark approval in 2022.
